Barclays analyst Matt Miksic maintained a Buy rating on Becton Dickinson (BDX – Research Report) today and set a price target of $278.00. The ...

Recently discovered on-chain evidence indicates Satoshi Nakamoto's legal name might be known by Kraken—provided a few ...

Bear-themed "proof-of-liquidity" chain Berachain, a rival to Solana and Ethereum, is now live with a massive airdrop.

BD plans to separate its Biosciences and Diagnostic Solutions unit into an independent company by fiscal 2026.

Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.43 in the first ...

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

Becton Dickinson (BDX) stock slid 3% after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate entities.

Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device ...

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences business.

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...